Pieris Pharmaceuticals, Inc. (PIRS)
| Market Cap | 201.15M |
| Revenue (ttm) | 31.70M |
| Net Income (ttm) | -37.81M |
| Shares Out | 56.30M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $3.48 |
| Previous Close | $3.42 |
| Change ($) | 0.06 |
| Change (%) | 1.75% |
| Day's Open | 3.41 |
| Day's Range | 3.40 - 3.54 |
| Day's Volume | 498,732 |
| 52-Week Range | 1.70 - 5.09 |
BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...
Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor to treat idiopathic pulmonary fibrosis (IP...
PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant to ...
These penny stocks are trending right now, here's why The post Best Penny Stocks to Buy Right Now? 15 To Watch In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Are you looking for cheap stocks with a lot of upside? Check out Rolls-Royce, Pieris Pharmaceuticals, and Kahoot!
BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...
Are these biotech penny stocks to watch on your list for July 2021? The post Best Biotech Penny Stocks to Buy Next Month?
Investing in penny stocks in June? Check these 3 out today The post Hot Penny Stocks to Buy?
Best Robinhood penny stocks for Summer 2021? Check these 4 out The post 4 Robinhood Penny Stocks to Watch in Summer 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....
Pieris Pharmaceuticals (PIRS) stock is rising higher on Wednesday after announcing a collaboration agreement with Genentech. The post PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Today ...
Investors need to pay close attention to Pieris (PIRS) stock based on the movements in the options market lately.
Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?
Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are trading higher by 57% at $2.91 after the company announced a respiratory and ophthalmology collaboration with Genentech. Pieris Pharmaceuticals is a c...
Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboratio...
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 58.82% and 141.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 0.00% over the past year to ($0.07), which beat t...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin thi...
On Monday, May 17, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...
Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the program,...
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in he...
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -8.33% and -50.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 5.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% over the past year to ($0.26)...
Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZen...
On Tuesday, March 30, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target coll...
BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno...
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -62.50% and -67.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2020 Results - Earnings Call Transcript
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.
NEW YORK, July 21, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).
Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q1 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q3 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The stock of Pieris Pharmaceuticals has made a nice move so far in September.
Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q2 2019 Results - Earnings Call Transcript
About PIRS
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment o... [Read more...]
| Industry Biotechnology | |
| CEO Stephen Yoder | Employees 111 |
| Stock Exchange NASDAQ | Ticker Symbol PIRS |
Financial Performance
In 2020, PIRS's revenue was $29.32 million, a decrease of -36.64% compared to the previous year's $46.28 million. Losses were -$37.23 million, 46.2% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for PIRS stock is "Strong Buy." The 12-month stock price forecast is 8.50, which is an increase of 144.25% from the latest price.